Literature DB >> 20956981

Synthetic lethal approaches to breast cancer therapy.

Farah L Rehman1, Christopher J Lord, Alan Ashworth.   

Abstract

The promise of personalized therapy for breast cancer is that therapeutic efficacy will be increased while toxic effects are reduced to a minimum. To achieve this goal, there is now an emphasis on the design of therapies that are based not only on the clinical manifestations of the disease, but also on the underlying molecular and cellular biology of cancer. However, identifying targets for personalized therapies in breast cancer is challenging. Here, we describe how biological concepts such as synthetic lethality and oncogene addiction can be used to identify new therapeutic targets and approaches. We discuss the current clinical developments in implementing synthetic lethality therapies, and highlight new ways in which this approach could be used to target specific subsets of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20956981     DOI: 10.1038/nrclinonc.2010.172

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


  77 in total

1.  Focus on recombinational DNA repair.

Authors:  Lorraine S Symington
Journal:  EMBO Rep       Date:  2005-06       Impact factor: 8.807

Review 2.  The concept of synthetic lethality in the context of anticancer therapy.

Authors:  William G Kaelin
Journal:  Nat Rev Cancer       Date:  2005-09       Impact factor: 60.716

3.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

Authors:  Soonmyung Paik; Steven Shak; Gong Tang; Chungyeul Kim; Joffre Baker; Maureen Cronin; Frederick L Baehner; Michael G Walker; Drew Watson; Taesung Park; William Hiller; Edwin R Fisher; D Lawrence Wickerham; John Bryant; Norman Wolmark
Journal:  N Engl J Med       Date:  2004-12-10       Impact factor: 91.245

4.  Inhibition of mutated, activated BRAF in metastatic melanoma.

Authors:  Keith T Flaherty; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Peter J O'Dwyer; Richard J Lee; Joseph F Grippo; Keith Nolop; Paul B Chapman
Journal:  N Engl J Med       Date:  2010-08-26       Impact factor: 91.245

Review 5.  Integrating genetic approaches into the discovery of anticancer drugs.

Authors:  L H Hartwell; P Szankasi; C J Roberts; A W Murray; S H Friend
Journal:  Science       Date:  1997-11-07       Impact factor: 47.728

6.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.

Authors:  Andrew Tutt; Mark Robson; Judy E Garber; Susan M Domchek; M William Audeh; Jeffrey N Weitzel; Michael Friedlander; Banu Arun; Niklas Loman; Rita K Schmutzler; Andrew Wardley; Gillian Mitchell; Helena Earl; Mark Wickens; James Carmichael
Journal:  Lancet       Date:  2010-07-06       Impact factor: 79.321

7.  Cancer. Addiction to oncogenes--the Achilles heal of cancer.

Authors:  I Bernard Weinstein
Journal:  Science       Date:  2002-07-05       Impact factor: 47.728

Review 8.  PTEN: a new guardian of the genome.

Authors:  Y Yin; W H Shen
Journal:  Oncogene       Date:  2008-09-18       Impact factor: 9.867

9.  Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair.

Authors:  Arun Gupta; Qin Yang; Raj K Pandita; Clayton R Hunt; Tao Xiang; Sandeep Misri; Sicong Zeng; Julia Pagan; Jessei Jeffery; Janusz Puc; Rakesh Kumar; Zhihui Feng; Simon N Powell; Audesh Bhat; Tomoko Yaguchi; Renu Wadhwa; Sunil C Kaul; Ramon Parsons; Kum Kum Khanna; Tej K Pandita
Journal:  Cell Cycle       Date:  2009-07-07       Impact factor: 4.534

Review 10.  Key signalling nodes in mammary gland development and cancer: Myc.

Authors:  Nancy E Hynes; Tina Stoelzle
Journal:  Breast Cancer Res       Date:  2009       Impact factor: 6.466

View more
  42 in total

1.  Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro.

Authors:  Anand G Patel; Silvana B De Lorenzo; Karen S Flatten; Guy G Poirier; Scott H Kaufmann
Journal:  Clin Cancer Res       Date:  2012-01-30       Impact factor: 12.531

2.  Inhibition of PARP1-dependent end-joining contributes to Olaparib-mediated radiosensitization in tumor cells.

Authors:  Annika Kötter; Kerstin Cornils; Kerstin Borgmann; Jochen Dahm-Daphi; Cordula Petersen; Ekkehard Dikomey; Wael Y Mansour
Journal:  Mol Oncol       Date:  2014-07-01       Impact factor: 6.603

3.  Triple-negative and basal-like breast cancer: implications for oncologists.

Authors:  J Lachapelle; W D Foulkes
Journal:  Curr Oncol       Date:  2011-08       Impact factor: 3.677

Review 4.  Opportunities and challenges provided by crosstalk between signalling pathways in cancer.

Authors:  A Prahallad; R Bernards
Journal:  Oncogene       Date:  2015-05-18       Impact factor: 9.867

5.  Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer.

Authors:  Svasti Haricharan; Nindo Punturi; Purba Singh; Kimberly R Holloway; Meenakshi Anurag; Jacob Schmelz; Cheryl Schmidt; Jonathan T Lei; Vera Suman; Kelly Hunt; John A Olson; Jeremy Hoog; Shunqiang Li; Shixia Huang; Dean P Edwards; Shyam M Kavuri; Matthew N Bainbridge; Cynthia X Ma; Matthew J Ellis
Journal:  Cancer Discov       Date:  2017-08-11       Impact factor: 39.397

Review 6.  Enhancing Career Paths for Tomorrow's Radiation Oncologists.

Authors:  Neha Vapiwala; Charles R Thomas; Surbhi Grover; Mei Ling Yap; Timur Mitin; Lawrence N Shulman; Mary K Gospodarowicz; John Longo; Daniel G Petereit; Ronald D Ennis; James A Hayman; Danielle Rodin; Jeffrey C Buchsbaum; Bhadrasain Vikram; May Abdel-Wahab; Alan H Epstein; Paul Okunieff; Joel Goldwein; Patrick Kupelian; Joanne B Weidhaas; Margaret A Tucker; John D Boice; Clifton David Fuller; Reid F Thompson; Andrew D Trister; Silvia C Formenti; Mary-Helen Barcellos-Hoff; Joshua Jones; Kavita V Dharmarajan; Anthony L Zietman; C Norman Coleman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-05-22       Impact factor: 7.038

Review 7.  Molecular biology of lung cancer: clinical implications.

Authors:  Jill E Larsen; John D Minna
Journal:  Clin Chest Med       Date:  2011-10-07       Impact factor: 2.878

8.  Cancer/testis antigens as molecular drug targets using network pharmacology.

Authors:  Anuj Kumar; Drista Sharma; M L Aggarwal; K M Chacko; Tarun Kumar Bhatt
Journal:  Tumour Biol       Date:  2016-10-05

Review 9.  What are we learning from the cancer genome?

Authors:  Eric A Collisson; Raymond J Cho; Joe W Gray
Journal:  Nat Rev Clin Oncol       Date:  2012-09-11       Impact factor: 66.675

Review 10.  Evolution of the cancer genome.

Authors:  Lucy R Yates; Peter J Campbell
Journal:  Nat Rev Genet       Date:  2012-10-09       Impact factor: 53.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.